AI Article Synopsis

  • The study investigates the expression of IL-1β in pancreatic islets during early type 1 diabetes, comparing new-onset diabetic patients with both non-diabetic and long-standing diabetic individuals.
  • Various pancreatic biopsy samples were analyzed for the presence of IL-1β alongside insulin and glucagon using immunostaining techniques, revealing significant variability in IL-1β-positive cells across different groups.
  • The findings suggest that IL-1β is more prevalent in insulin-positive islets of diabetic patients, with varying patterns of expression indicating a complex role of IL-1β in beta cell destruction during the progression of diabetes.

Article Abstract

Aims/hypothesis: Although IL-1β is considered a key mediator of beta cell destruction, its cellular expression in islets during early type 1 diabetes remains unclear. We compared its expression in rare pancreatic biopsies from new-onset living volunteers with its expression in cadaveric pancreas sections from non-diabetic autoantibody-positive and -negative individuals and those with long-standing disease.

Methods: Pancreatic biopsy sections from six new-onset living volunteers (group 1) and cadaveric sections from 13 non-diabetic autoantibody-negative donors (group 2), four non-diabetic autoantibody-positive donors (group 3) and nine donors with diabetes of longer duration (0.25-12 years of disease; group 4) were triple-immunostained for IL-1β, insulin and glucagon. Intra- and peri-islet IL-1β-positive cells in insulin-positive and -negative islets and in random exocrine fields were enumerated.

Results: The mean number of IL-1β-positive cells per islet from each donor in peri- and intra-islet regions was <1.25 and <0.5, respectively. In all study groups, the percentage of islets with IL-1β cells in peri- and/or intra-islet regions was highly variable and ranged from 4.48% to 17.59% in group 1, 1.42% to 44.26% in group 2, 7.93% to 17.53% in group 3 and 3.85% to 42.86% in group 4, except in a single case where the value was 75%. In 25/32 donors, a higher percentage of islets showed IL-1β-positive cells in peri-islet than in intra-islet regions. In sections from diabetic donors (groups 1 and 4), a higher mean number of IL-1β-positive cells occurred in insulin-positive islets than in insulin-negative islets. In group 2, 70-90% of islets in 3/13 sections had weak-to-moderate IL-1β staining in alpha cells but staining was virtually absent or substantially reduced in the remaining groups. The mean number of exocrine IL-1β-positive cells in group 1 was lower than in the other groups.

Conclusions/interpretation: At onset of type 1 diabetes, the low number of islet-associated IL-1β-positive cells may be insufficient to elicit beta cell destruction. The variable expression in alpha cells in groups 2-4 suggests their cellular heterogeneity and probable physiological role. The significance of a higher but variable number of exocrine IL-1β-positive cells seen in non-diabetic individuals and those with long-term type 1 diabetes remains unclear.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00125-018-4600-8DOI Listing

Publication Analysis

Top Keywords

living volunteers
12
pancreatic biopsies
8
type diabetes
8
donors diabetes
8
diabetes longer
8
longer duration
8
new-onset living
8
sections non-diabetic
8
non-diabetic autoantibody-positive
8
donors group
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!